EMPATHY NSCLC: European Registry for Plasma-Based Molecular Profiling in Advanced NSCLC Patients
- Conditions
- NSCLC (Advanced Non-small Cell Lung Cancer)
- Registration Number
- NCT07096258
- Lead Sponsor
- Hedera Dx SA
- Brief Summary
The goal of this registry is to capture real-world data from plasma- and tissue-based molecular profiling, treatments, outcomes and patient-reported outcomes from patients with advanced or metastatic non-small cell lung cancer (NSCLC). The main objective of the study is to better understand the real-world clinical practice of the use and utility of molecular tumour profiling, the choice of treatment, and the outcome after such molecular profiling and treatment.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 1000
- Locally advanced or metastatic, unresectable NSCLC, stages IIIB/C or IV, who have not previously been treated for this advanced disease.
- Intention-to-initiate first-line tumour therapy for this advanced disease.
- Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2.
- At least 18 years of age on the day of signing informed consent, and capable of signing informed consent.
- Any known non-cutaneous malignancy (except for this NSCLC and early-stage non-invasive cervical cancer) that has occurred within 5 years prior to enrolment.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Actionable biomarkers At baseline Proportion of patients with successful molecular profiling and detectable actionable biomarkers
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (4)
Université de Lorraine
🇫🇷Nancy, Lorraine, France
University of Naples "Federico II"
🇮🇹Napoli, Italy
General Universitario Gregorio Marañon
🇪🇸Madrid, Spain
Hôpitaux Universitaires Genève
🇨🇭Geneva, Switzerland
Université de Lorraine🇫🇷Nancy, Lorraine, France